Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: Exp Dermatol. 2011 Dec;20(12):959–968. doi: 10.1111/j.1600-0625.2011.01389.x

The Itchy scalp - scratching for an explanation

Ghada A Bin saif 1,2, Marna E Ericson 3, Gil Yosipovitch 2,4
PMCID: PMC3233984  NIHMSID: NIHMS331222  PMID: 22092575

Abstract

Scalp pruritus is a common complaint that is considered a diagnostically and therapeutically challenging situation. Scalp skin has a unique neural structure that contains densely innervated hair follicles and dermal vasculature. In spite of the recent advances in our understanding of itch pathophysiology, scalp itching has not been studied as yet. In this review, we summarize the current knowledge on the neurobiology of scalp and hair follicles as well as itch mediators and provide a putative mechanism for scalp itch with special emphasis on neuroanatomy and pathophysiology.

Keywords: Pruritus, Innervation, Scalp, Hair follicle


Scalp pruritus is a common and distressing symptom. It is most commonly associated with seborrheic dermatitis and psoriasis but appears often without any noticeable skin lesion or obvious diagnosis. It is considered a diagnostically and therapeutically challenging situation particularly when no other body part itches and no detectable lesion seen (1). The focus of this review is to describe the putative mechanism of scalp itch with special emphasis on neuroanatomy and pathophysiology.

Epidemiology of scalp pruritus

Although scalp itch is considered common, there is a paucity of data published on its prevalence (2). In a study conducted on a quantitatively representative sample of the French population, scalp itching was reported in 25% of the population (3). In patients with generalized idiopathic pruritus, 13% showed involvement of the scalp (4).

Causes of scalp pruritus

Scalp pruritus can arise from a variety of conditions including dermatologic, systemic, neurologic and psychogenic diseases. Among patients with psychogenic pruritus, the most commonly affected sites are scalp and face (5). Scalp pruritus can be classified based on the potential underlying disease (Table 1).

Table 1.

proposed clinical classification of scalp pruritus According to potential underlying disease*

Dermatologic: (arising from diseases of the skin in order of frequency)
Inflammatory dermatoses: seborrheic dermatitis, psoriasis, advanced aging itch and skin xerosis
atopic dermatitis 7, contact dermatitis, sensitive scalp 3, lichen planopilaris 8, 9, Frontal fibrosing alopecia 10, central centrifugal cicatricia alopecia 11, Pityriasis amiantacea 12, xerosis, active phase of alopecia areata, urticaria, scars, insect bite, lichen simplex chronicus, lichen nuchae, discoid lupus erythematosus, acne necrotica, folliculitis decalvans 13, Angiolymphoid hyperplasia with eosinophilia 14.
Infectious dermatoses: folliculitis, mycotic, bacterial and viral infections, scabies, pediculosis capitis, cutaneous larva migrans.
Autoimmune dermatosis: dermatitis herpetiformis.
Neoplasms: lymphoma, leukemic infiltrates of the skin.
Neuropathic: (arising from diseases or disorders of afferent nerve fibers)
Diabetes mellitus 15, Post herpetic neuralgia, migraine headache, atypical facial neuralgia, scalp dysesthesia 16, brain and spinal cord injury17, Narrowing of the bony foramina from osteoarthritis17, Wallenberg syndrome 18, brain tumors 19 .
Systemic: (arising from diseases of organ)
Chronic renal failure, cholestatic liver disease, Lymphoma- Hodgkins and non hodgkins, dermatomyositis 20, 21, drug induced pruritus (e.g dobutamine) 22, Eosinophilic arteritis of the scalp 23.
Psychogenic/psychosomatic: (somatoform pruritus with co-morbidity of psychiatric and psychosomatic diseases)
Obsessive compulsive disorders, anxiety disorders, Somatoform and dissociative disorders, tactile hallucinations, delusional parasitosis, schizophrenia, depression
*

Source: with modification from (1,6).

Major dermatologic conditions associated with scalp pruritus

Seborrheic dermatitis

The most common presentation of scalp pruritus occurs in the setting of seborrheic dermatitis (24). Pathogenesis of seborrheic dermatitis is complex and appears to result from interactions among scalp skin, sebaceous secretions, Malassezia fungi, and the cutaneous immune system (25). In seborrheic dermatitis, yeast fails to possess lipid layer because of alterations in the availability of nutrients on the lipid surface, this may explain the inflammatory nature of this itchy dermatosis (see below malassezia species) (26,27).

Kerr et al. suggested an association between the subjective perception of itch in the scalp of seborrheic dermatitis patients and the level of histamine in the skin. They reported also that the scalp histamine level in subjects with seborrheic dermatitis was more than twice that in those without it. Treatment with a commercial potentiated zinc pyrithione shampoo led to a reduction in histamine in subjects with dandruff to a level that was statistically indistinguishable from those who did not have dandruff. This reduction in histamine was accompanied by a highly significant reduction in the perception of itch intensity (28).

Scalp Psoriasis

A recent large survey of 195 psoriatic patients showed that 58% suffer from scalp pruritus (7). Another survey in moderate to severe chronic-plaque psoriasis revealed regional variations in the sites of pruritus; the most affected anatomical site was the scalp (50%). Itching was limited to psoriatic lesions (70% of cases) (29).

Scarring alopecias

Scalp itching is commonly encountered in patients with lichen planopilaris when inflammation is present (30). Scalp pruritus is seen in approximately 70% of patients (8,9). Central centrifugal cicatricial alopecia is a common cause of scarring alopecia in African American women and is frequently associated with scalp itching or tenderness, with variable degrees (31).

Neuropathic itch

Neuropathic itch in scalp can be seen in association with diabetes mellitus, and herpes zoster (15,32). Scribner observed several patients whose primary complaint of pruritus confined to the scalp proved to be caused by unsuspected diabetes. Complete relief of the pruritus was achieved with control of the underlying diabetes (15).

Post herpetic neuralgia (PHN) has been historically associated with pain. However data emerged that PHN also induces Post herpetic itch (PHI) (32). A large epidemiological study reported PHI in roughly half of PHN patients. PHI can coexist with PHN or occur alone. PHI is more likely after zoster of the head and neck, particularly in the Trigeminal (V1) dermatome (33).

In a patient with PHI on the scalp, quantitation of PGP 9.5-immunoreactive epidermal nerves demonstrated loss of 96% of PGP 9.5 stained epidermal innervation in the itchy area. Concomitantly, quantitative sensory testing indicated severe damage to most sensory modalities except itch. Possible mechanisms include selective preservation of peripheral itch-fibers from neighboring unaffected dermatomes, imbalance between excitation and inhibition of second-order sensory neurons, and/or electrical hyperactivity of hypo-afferented central itch specific neurons (32). Oaklander has suggested that the excessive scratching observed in some patients with PHI may be due to a reduced sensation of pain (34). Normally, the act of scratching to relieve itch elicits mild pain, which provides a protective negative feedback to halt further scratching. In PHI, scratching the affected skin area elicits no pain, so that scratching persists unabated, sometimes to the point of severe skin damage (34). Ross et al. recently demonstrated the existence of itch inhibitory interneurons within the dorsal horn. Bhlhb5 mutant mice lacking these interneurons had persistent itch (35). Glutamate is one of the major excitatory neurotransmitters in the spinal cord and may have a role in these interneurons. Therefore drugs suppressing presynaptic glutamate-release such as gabapentin and pregabalin may inhibit certain subtypes of itch such as neuropathic itch via this pathway (36).

Sensitive scalp

Sensitive skin is characterized by subjective complaints of discomfort without predictable classical visible signs of irritation and without an immunologic response (37,38). It was found that 36% of 400 subjects in 2 hospitals declared that they had sensitive skin on scalp (39). Further epidemiological studies revealed that 44% and 32% subjects declared suffering from sensitive scalp (3,40). Itching affects about 60% of subjects with sensitive scalp (40). In addition, hair loss was significantly associated with scalp sensitivity(3).

Pathophysiology of itch in the scalp

The pathogenesis of scalp pruritus has rarely been investigated. In order to better understand why the scalp is so itchy it is important to understand the neuroanatomy of the hair follicle in its different cycles.

The Scalp is a complex neural structure for itch

The sensory innervation of the scalp conducted through branches from the trigeminal nerve, cervical plexus and dorsal rami of the cervical nerves (Figure 1). The hair follicle (HF) is highly innervated with four types of specific nerve endings (41,42). These are: free nerve endings (nociceptors), lanceolate nerve endings (acceleration detectors), Merkel nerve endings (pressure detectors), and pilo-Ruffini corpuscles (tension detectors) (43). The free nerve endings innervating the HF are from A-delta (thinly myelinated) or C fibers (unmyelinated) that emerge from the superficial nerve plexus. These nerves terminate as free nerve endings in the connective tissue between the sebaceous gland and HF (Figure 2) (44). Furthermore, HF development and cycling do affect the HF innervations. Peters et al. showed that cutaneous and follicular neuropeptide-containing NFs express major hair-cycle-associated changes (45). Initially, epidermal innervation is very dense, while it decreases and gains neuropeptide expression after penetration of HFs through the epidermis. Here, the number of neuropeptide containing NFs increases during the anagen phase of HF, decreases during the catagen phase, and stays low in the telogen phase as do their contacts with mast cells (MCs) (46).

Figure 1. Sensory innervations of the scalp.

Figure 1

V1: Ophthalmic division of trigeminal nerve; V2: Maxillary division of the trigeminal nerve; V3: Mandibular division of the trigeminal nerve; C2: Second cervical nerve; C3: Third cervical nerve.

Figure 2. Innervation around a human scalp hair and melanocytes of the dermal papilla and epidermis.

Figure 2

Projection of 55 one-micron optical sections of human scalp hair follicle captured using laser scanning confocal microscopy.

4-mm punch biopsy from human scalp, was cryo-sectioned into 180-micron, vertical section. Sample was immunostained with antibodies to a pan-neuronal marker PGP9.5 (pseudo-colored aqua), and Mel5 (pseudo-colored yellow). 100XMAG

In addition to HF, the scalp has abundant blood vessels more than in any other body region (47,48). There are also cyclic changes of perifollicular vascularization. Yano et al. found a significant increase in perifollicular vascularization during the anagen phase of HF, followed by regression of angiogenic blood vessels during the catagen and telogen phases (49). Pruritus involves different classes of cutaneous unmyelinated, slowly transmitting, sensory C-NFs that are distributed in the epidermis and papillary dermis. They are of two types; mechano-insensitive that are activated by histamine, and mechano--sensitive that cause pruritus with burning when induced activated by cowhage spicules (Mucuna pruriens) (50,51). Two systematic quantifications of epidermal NF density in multiple body sites revealed that scalp epidermal NF density was comparable to the back, but less than the cheek, neck and distal limbs (52,53). This variability in NF density may explain the topographical distribution of sensory thresholds in human skin to temperature as well as itch and pain (54). Informative data, namely distribution of C-fibers at various body sites, is lacking. This data will be the key to better understanding of the topographical distribution of itch sensation in humans.

Are there differences in sensation between scalp and other skin areas?

Although the scalp is considered extremely itchy in many cutaneous inflammatory diseases and as mentioned above highly innervated, experimental itch studies in humans were not able to demonstrate lower itch thresholds. Rukwied et al. reported that forearm was more itch-sensitive than the scalp when investigated by histamine intradermal microdialysis, whereas topical application of histamine demonstrated that scalp was more itch-sensitive than the forearm skin (55). Shelly and Arthur had also demonstrated differences in itch perception among various areas of the body by the insertion of cowhage spicules, which activate Proteinase activating receptor 2 (PAR-2), an important non histaminergic itch pathway (see below) (56). In their studies, the scalp showed no response to cowhage spicules (57). Furthermore, hand and ankle were more sensitive to electrically evoked itch as compared to head and neck (58). These data corroborate with Essick et al. findings who studied the thresholds for detection of cooling, warming, cold pain and heat pain. They found that the scalp was notably less sensitive to thermal stimulation compared to other body areas, regardless of specific sensation considered (59). Whether these differences in thermal sensitivity between body sites is related to spatial variation in the density of thermal receptors or to differences in central neural processing is a matter of debate (59-63). Our recent preliminary study performed on scalp thermal and pain thresholds, as well as assessment of scalp itch using both histamine and cowhage revealed comparable result to the data above (unpublished data).

Cutaneous sensory receptors and mediators involved in itchy scalp (Figure 3)

Figure 3. Itch mediators in the scalp.

Figure 3

Scalp pruritus involves a complex interaction between different cells, mediators and receptors, most of them are shown above.

PAR-2, proteinase-activated receptor 2; H1R, Histamine 1 receptor; H3R, Histamine 3 receptor; H4R, Histamine 4 receptor; NGF, nerve growth factor; ET-1; TrkA, high-affinity NGF receptor; endothelin-1; ETAR, endothelin receptor A; eCB, endogenous cannibinoids; NT-3, neurotrophin 3; NT-4, neurotrophin 4; LTB4, leukotriene B4; TXA2, thromboxane A2; GRP, gastrin-related peptide; SP, substance P; CGRP, calcitonin gene related peptide; Mrgpr, mas-related G protein-coupled receptor; IL-2, interleukin-2; IL-4, interleukin-4; IL-8, interleukin-8; IL-31, interleukin-31; BDNF: brain-derived neurotrophic factor; EDN, eosinophil-derived neurotoxin; ECP, eosinophil cationic protein; PGD2, prostaglandin D2; ORS, outer root sheath; IRS, inner root sheath; CB1, cannabinoid receptor1; CB2, cannabinoid receptor2; NK1R, neurokinin-1 receptor; TRPV, transient receptor potential vanilloid; MOR, Mu-opioid receptor.

MCs and Histamine receptors

Histamine is the prototype of endogenous itch mediator secreted from MCs and can induce pruritus via H1 and H4 receptors on NFs (64,65), whereas H3 receptors appear to be involved in the suppression of pruritus (66). MC can induce pruritus directly also through the release of other mediators such as chymase, tryptase and cytokines. MC also secrete neurotrophins such as nerve growth factor (NGF) that contribute to hyperplasia of NFs in chronic pruritus forms, as has been observed in Atopic dermatitis (AD) (54,64,65). MCs function also as hair cycle regulators and are involved in the control of HF regression in murine system (67,68). MC number, degranulation activity, histochemical staining characteristics, histamine/heparin skin content, and physical MC-NF contacts all fluctuate significantly during synchronized HF cycling in rodent skin (69,70). MC density in scalp skin does not differ significantly from that in forearm skin (71). MCs number in skin has been reported to increase in AD and in the pruritic lesions of psoriasis (71,72).

PAR-2

PAR-2 is a G-protein coupled receptor. PAR-2 plays major role in mediating chronic pruritus. During neurogenic inflammation, various endogenous serine proteases such as trypsins from keratinocytes and tryptase from MCs activate PAR-2 on sensory nerve ending to release calcitonin gene-related peptide (CGRP) and substance P (SP) (73). PAR-2 signaling also stimulates the release of neuropeptides from central nerve endings thereby activating CGRP receptor and SP receptor (NK1R) to transmit itch responses to the central nervous system (74). Recently, it was shown that Cathepsin S which is an endogenous cystein protease evokes itch and activates PAR-2 and 4 (75). Exogenous activators of PAR2 may be serine proteinases generated by bacteria, fungi, and house dust mites (76). PAR-2 interacts synergistically with transient receptor potential vanilloid-type 1 (TRPV1), thereby amplifying itch sensation (see below) (77). In the skin, PAR-2 is expressed by almost all cell types including keratinocytes, HF, sensory neurons, and MCs (78-80). In human HF, PAR-2 is confined to the Inner root sheath (IRS) (79). PAR-2 activation is likely to be involved in pruritus of AD (56,81). In addition, skin exposure to exogenous microbial proteases could also induce itch and inflammation via PAR-2 (81). This could explain why staph folliculitis in the scalp is extremely itchy. Frateschi et al. showed that increased expression of epidermal PAR2 In transgenic mice causes epidermal hyperplasia, ichthyosis and itching (82).

TRPV1

TRPV1 receptor is activated by capsaicin, the key ingredient of hot chilli peppers. In addition to capsaicin, TRPV1 can also be activated by heat, acidosis and endogenous endovanilloids such as arachidonic acid derivatives, lipid peroxidation metabolites, and endocannabinoids (83,84). When TRPV1 is activated, it causes burning pain, itching and heat sensation, which is suppressed by continuous activation (51). TRPV1-expressing neurons are required for the behavioral responses to several different pruritic compounds including histamine, serotonin, and endothelin-1. TRPV1-expressing neurons have multiple intracellular mechanisms that generate or mediate itch (85). TRPV1 is highly expressed on sensory NFs, epidermal keratinocytes, HFs, dermal blood vessels, MCs, sebaceous glands and eccrine sweat glands (86,87). In human HF, TRPV1 is confined mainly to the Outer root sheath (ORS) and hair matrix (see Figure 3). TRPV1 has a significant role in human hair growth control. In organ culture, TRPV1 activation by capsaicin resulted in hair shaft elongation, suppression of proliferation, induction of apoptosis, premature HF regression (catagen), and up-regulation of intrafollicular transforming growth factor-B2. Cultured human ORS keratinocytes also expressed functional TRPV1, whose stimulation inhibits proliferation, induces apoptosis, up-regulate known endogenous hair growth inhibitors (interleukin-1B, transforming growth factor-B2), and down-regulate known hair growth promoters (hepatocyte growth factor, insulin-like growth factor-I, stem cell factor) (88). In rat skin, hair growth retardation, along with alopecia and a decrease in hair shaft thickness, follows as a consequence of capsaicin-induced sensory denervation (89). Pirt gene was recently identified as a regulator of TRPV1, in both histaminergic and nonhistaminergic itch (90). Tacrolimus has been reported to have anti-itch property, unrelated to its anti inflammatory property. This was explained possibly by a desensitization of TRPV1 and calcium currents through the phosphatidylinositol 4,5-bisphosphate regulation pathway (91). It would be of great interest to examine the role of TRPV1 receptor and its ligands in itchy scalp. We suspect that there could be significant differences in distribution and activity of TRPVs in itchy scalp.

Another thermosensitive Transient Receptor Potential channel which has been shown to have a role in itch in mice is TRPV3 (92). TRPV3 is abundantly expressed in keratinocytes and scalp HF, mainly the ORS (93-95). Activation of TRPV3 shown recently to inhibit human hair growth. In organ culture, TRPV3 activation resulted in a dose-dependent inhibition of hair shaft elongation, suppression of proliferation, and induction of apoptosis and premature HF regression (catagen) (95).

Mas-related G protein-coupled receptor (Mrgpr)

Mrgpr family can be activated directly by peptides with common C-terminal motifs like RFamide, -RYamide, -RYG or -RLamide, neuropeptide AF, γ2-melanocyte-stimulating hormone, bovine adrenal medulla8-22 peptide [BAM8-22] and chloroquine (96-100). Recently, direct evidence proved the involvement of some of these peptides in itch sensation. Mouse MrgprA3 and MrgprC11 act as itch receptors in the skin for the pruritogens chloroquine, and bovine adrenal medulla 8-22 peptide (BAM8-22) and synthetic peptide Ser-Leu-Ile-Gly-Arg-Leu (SLIGRL) respectively (96,97,101). Interestingly, human MrgprX1 can respond to both chloroquine and BAM8-22 (97).

In human MrgprXs expression was detected exclusively in DRG neurons (99). MrgprA3 and MrgprC11 are expressed in a subset of TRPV1-positive afferent nerves (97), though TRPA1 is required for Mrgpr-mediated signaling (102).

Opioid receptors

Opioids and their receptors in the skin comprise part of the endogenous opioid system. It includes three opioid receptors: Mu (MOR), Delta (DOR) and Kappa (KOR), and the opioid peptides, such as enkephalins, endorphins, dynorphins and endomorphins. It is widely accepted that KOR signaling suppresses itch, while MOR signaling can stimulate itch. MOR seems to be important in chronic forms of pruritus, while KOR agonists are important in acute itching (103). Neuronal communication between pain- and itch-transmitting neurons underlies the role of opioids in pruritus (104). Many painful stimuli shown to inhibit itch by activating specific nociceptive pathways and spinal cord as well as higher CNS structures. On the other hand, opioids that activate spinal opioid receptors which induce analgesia (e.g. MOR agonists like morphine) may reduce the inhibition of itch by pain, thus enhancing pruritus (105-108). Itch and pain neurons in the spinal cord are connected by opioid-sensitive interneurons that can inhibit the pruritus transmission. Suppression of the activity of these interneurons by opioids results in clinically relevant itch sensation (104). Pruritus occurs in about 2-10% of patients treated systemically with opioids. But the risk is higher with intrathecal morphine reaching up to 100% (109-111). Intrathecal or epidural Opioid-induced itch frequently involves trigeminal skin in human and monkey (109,112). This phenomenon could be explained by the high concentration of opioid receptors in the spinal nucleus of the trigeminal nerve innervating facial areas (109).Opioid receptors are located in both peripheral and central nervous system, as well as epidermal keratinocytes, fibroblasts, melanocytes and hair follicles (103). In HF, Follicular dermal papilla (FP) mesenchyme and follicular epithelium consistently shows prominent MOR expression throughout the hair cycle (103). B-endorphin immunoreactivity is detected in the keratinocytes of the HFs in scalp (113). B-endorphin was localized to keratinocytes of the follicular matrix or the outer the ORS of the HF (113). B-endorphin expression is weakly detectable in the hair growth-inductive FP during anagen. However, B-endorphin immunoreactivity becomes more readily detectable in the FP during catagen and telogen, as well as in the HF epithelium (103). Tominaga et al. observed a down regulation of KOR, not MOR, in the epidermis of patients with AD, while ultraviolet treatment of this disease down regulated MOR but restored KOR expression (114). Furthermore, antipruritic efficacy of MOR antagonists has been reported in various dermatologic and systemic diseases including prurigo nodularis, chronic urticaria and cholestatic pruritus (104). Among the MOR antagonists, Naltrexone and Nalmefene achieve a significant antipruritic relief in atopic dermatitis (104,115,116). KOR agonists also exhibit a potent antipruritic activity. Among them, Nalfurafine is a selective KOR agonist that shows a potent antipruritic effects in hemodialysis patients with uremic pruritus (117,118) Moreover, Butorphanol is a KOR agonist and a weak MOR antagonist, shown to be effective in alleviating acute opioid induced itch and intractable pruritus (119).

Cannabinoid receptors (CBs)

Cannabinoid receptors mediate the psychopharmacological action of marijuana (120). Activation of the cannabinoid receptors CB1 and CB2 leads to inhibition of pruritus. Cannabinoid receptors present in the nervous and immune system. In the skin, CB1 and CB2 were observed in cutaneous NFs, MCs, macrophages, epidermal keratinocytes, and the epithelial cells of HFs, sebocytes and eccrine sweat glands. The expression of CB1 and CB2 on cutaneous nerves was identified in large myelinated NFs of the reticular dermis, in small unmyelinated nerves of the papillary dermis, at the dermal—epidermal junction, and occasionally within the epidermis and small NFs associated with HFs. In skin specimens of different body sites (face, head, trunk and extremities) distribution of CB1 and CB2 immunoreactivity on cutaneous nerves was identical. In HFs, the differentiated epithelial cells of the infundibulum and the IRS stained for CB1. In contrast to the recorded CB1 staining, undifferentiated cells of the infundibulum, the ORS and the bulb of HFs stained for CB2, but the IRS was negative (121). The abundance of these receptors in the HF may suggest they have endogenous antipruritic role attenuating the itch response. Further studies are required to elucidate their exact role in itchy scalp.

Neurokinin receptors (NKRs)

The neuropeptide SP is reported to be a putative mediator for itching directly; and indirectly through MC activation. After release from sensory nerve endings, it binds with high affinity to the neurokinin-1 receptor (NK1R) on keratinocytes, endothelial cells and MCs. This attracts proinflammatory cells, degranulates MCs with release of pruritogenic proinflammatory cytokines such as tumor necrosis factor-alpha or leukotriene B4 (51).

SP content in the skin was assessed by radioimmunoassay and high-performance liquid chromatography and found to be moderately high in scalp but less than in face (122). In healthy human scalp NK1R is expressed on epidermal keratinocytes, NFs, sebaceous gland, dermal microvascular cells and sweat glands. NK1R expression in anagen HF is localized to the distal, suprainfundibular ORS, IRS and the nucleated hair shaft but weaker expression in HF matrix, and ORS (123).

The murine HF is richly innervated by sensory NFs expressing the neuropeptide SP that are located in close vicinity to the HF bulge region (45). Cutaneous SP expression and the number of SP-immunoreactive NFs are significantly increased during the early anagen phase of the murine hair cycle (45,124). More recently, SP has been described as being capable of inducing hair growth or inhibiting it in murine system. SP effects on the HF are strictly hair cycle-dependent (45,124,125). Furthermore, SP found to be a central element in the stress-induced threat to HF, resulting in premature onset of catagen accompanied by MC activation in the skin and subsequent release of mediators and secretion of NGF (126). This increase in SP and NGF during psychological stress might explain the stress related aggravation of scalp itch in diseases such as seborrhoeic dermatitis and scalp psoriasis (127).

CGRP

CGRP can provoke itch when released as a consequence of C-fiber activity. C-fiber activity leading to the itch sensation in the central nervous system also leads to CGRP release in the periphery where it provokes vasodilatation as one of the features of neurogenic inflammation; however, CGRP may be involved in opioid-mediated mechanism of itch perception (128). In addition, CGRP potently enhances brain-derived neurotrophic factor (BDNF) release from cultured trigeminal neurons in vivo in rats (129). CGRP content in the scalp has been assessed by radioimmunoassay and high-performance liquid chromatography and found to be low compared to other cutaneous regions (122). CGRP has been shown to co-localize with SP in human skin, occurring in the dermal papillae, and free epidermal nerve-endings of glabrous skin (130). In murine skin, the number of CGRP immunoreactive single NFs increased significantly during anagen, compare to telogen (45). CGRP inhibited anagen progression (45).

CGRP is involved in the pruritus of AD and Psoriasis (131-133). Repeated application of capsaicin desensitizes the nerve endings such that they no longer respond to local stimuli, and re-accumulation of CGRP and SP is inhibited. This explains the high efficacy of topical therapy with capsaicin in itch (134).

Neurotrophins (NTs)

Three members of the NT family have been identified as molecular players in the pathogenesis of itch: NGF, BDNF, NT3, and NT4 (135-138). It has been suggested that the increased production and release of NGF and NT4 from resident skin cells such as Keratinocytes, MC, fibroblasts and eosinophils causes proliferation of unmyelinated afferent nerve terminals (135,138). NGF also leads to an increase in MC and induces tryptase release from mast cells (108,139). NGF, NT-3 and NT-4 acutely sensitize sensory afferents and up-regulate the expression of neuronal neuropeptides especially SP and CGRP, and certain receptors (e.g TRPV1) which can worsen existing pruritus or cause it to persist (108,140). NGF and its high-affinity NGF receptor (TrkA) proteins are both expressed in human scalp skin and HF. Higher expression was found in anagen as compared with either catagen or telogen HF. In the anagen HF, high expression values were seen in the distal region, followed by upper central, lower central and bulb regions for both NGF and TrkA (141). NGF immunoreactivity was mainly detected in the ORS, IRS, FP, and connective tissue sheath, while TrkA was mainly detected in the ORS and IRS (141). Peters et al. suggest an anagen-promoting or anagen-supporting role for NGF and TrkA, and a catagen-promoting role for proNGF/ pan-neurotrophin-receptor (p75) interactions (142). NGF has recently been described as a stress-associated growth factor (143,144), and is one of the key catagen-inducing factors involved in stress-mediated hair growth inhibition in the mouse (145). In AD, Keratinocytes express high levels of NGF, NT-4 and TrkA, and high plasma levels of NGF are found (138,146-148). Although, recent studies demonstrate low plasma and dermal levels of NGF in AD patients (149,150). BDNF levels were also increased in serum, plasma, and oesinophils of AD patients compared with healthy controls (151). BDNF levels were correlated with the nocturnal scratching activities in AD (137). In addition to the sprouting of epidermal NFs that is initiated by increased NGF in AD (152). It was found also that Anti-NGF is antipruritic in animal models of AD (153-154). Increased fiber density and higher local NGF concentrations were also found in patients with pruritic contact dermatitis (155), and increased NGF, and TrkA immunoreactivities were detected in prurigo nodularis (156), and in pruritic lesions of patients with psoriasis (132).

Gastrin-related peptide receptor (GRPR)

GRPR is a G protein-coupled receptor for GRP, a bombesin-like peptide. The GRP/GRPR system in the spinal cord of mice has a pivotal role in itch signaling but not pain perception. It is strongly activated by histamine-independent mechanisms such as by PAR-2 agonist and chloroquine (157,158). GRP, its ligand is expressed on nerves, keratinocytes, hair follicle, blood vessels, eccrine sweat glands, sebaceous glands and erector pili muscle; though this morphological data are poorly substantiated as it was studied using only one polyclonal antibody (159,160). GRP is co-localized with TRPV1 in cutaneous NFs (108). GRP NFs found to be more abundant in skin of AD mice, but the role of this receptor in humans remains to be defined (161).

Endothelin (ET)

ET-1 evokes pruritus/itching sensation in both humans and animals. It is released from endothelium and MCs (135,162,163). Interestingly, an anti-nociceptive effect of endothelin1 was found when injected to hairy skin of the rat (164).

Cytokines

Certain interleukins (IL) are implicated in the pathogenesis of pruritus. Among them, IL-2 elicits rapid, low pruritogenic effects using skin-prick testing of healthy volunteers (165). It induces itch by activation of a discrete population of cutaneous C-polymodal nociceptors that are chemosensitive to endogenous inflammatory mediators including histamine and bradykinin (166). IL-2 is considered a possible pruritogenic mediator in AD and Psoriasis (72,167,168). Moreover, recombinant IL-2 was shown to induce pruritus when administered to cancer patients (169). IL-31 has been suggested as a pruritic cytokine. IL-31 ligand is released by Th2 lymphocytes. Its receptor IL-31 RA is expressed by keratinocytes, macrophages, dendritic cells, and probably sensory nerves projecting into the dorsal horn of the spinal cord (170,171). It has a significant role in AD itch (172,173). Another pruritogenic cytokine found in AD is IL-8 (174-177). Furthermore, mice overexpressing IL-4 in the epidermis spontaneously developed a pruritic inflammatory skin disease resembling human AD (178).

Inflammatory cells other than MCs

Basophilic granulocytes can release histamine similar to MCs and thus contribute to the induction of pruritus (179). Basophils have a proven role in aquagenic itch and in chronic idiopathic urticaria (180,181).

Eosinophilic granulocytes have a role in inflamed skin pruritus through the release neurotoxic granule proteins such as eosinophil cationic protein (ECP); neurotrophins such as NGF and BDNF; and neuropeptides such as SP. Accumulation of ECP in lesional skin and BDNF correlates with the severity of pruritus and disease activity of AD respectively (51). Eosinophils express histamine receptors including the H4 receptor (184). Furthermore, eosinophils hematopoiesis, activation, survival, and elaboration of mediators can all be regulated by mast cells in tissue. Moreover, because eosinophils can secrete stem cell factor, they can regulate mast cell function in a paracrine manner (183).

Other non neuronal unique properties of scalp that may play role in scalp itch

Scalp microflora

The scalp normally harbors many micro-organisms including in particular Malassezia species, staphylococci and Propionibacterium species (24,76,184).

A- Malassezia species may have a dual effect on scalp itch- protective in healthy skin and itch inducing in sebum abnormalities

The highest density of Malassezia species is found in scalp (185). In normal condition, Malassezia yeast significantly reduces the production of pro-inflammatory cytokines by keratinocytes, which is related to the presence of lipid-rich microfibrillar layer surrounding yeast cells (186). High quantity of lipid may prevent the yeast cell from inducing inflammation while low lipid content will reverse this protective mechanism (27,187). This was proven when extraction of cell-wall lipids of all species of Malassezia reversed their capacity and increased IL-6, IL-8 and IL-1a production above levels elicited by the capsulated forms. Notably, acapsular viable, stationary phase M. globosa caused a 66-fold increase in IL-8 production (27,187). In the author opinion, this may contribute the etiology of seborrheic dermatitis itch.Furthermore, Malazzesia species have lipase activity, which hydrolyze human sebum triglycerides in to free fatty acids (FFAs) (25), consume specific saturated fatty acids, and leave behind the unsaturated lipids. The unsaturated fatty acids are well know irritants and can induce inflammation including elevating IL-la and IL-8 levels (188-191). The unsaturated fatty acids effect on the skin is well controlled by intact stratum corneum barrier function (192,193).

Malassezia species have been identified as a causative organism or aggravating factor in various pruritic skin diseases, including pityrosporum folliculitis, seborrheic dermatitis and AD (194,195). AD patients with sensitivity to P.orbiculare are characterized by severe itch disturbing sleep. They suffer also from a more chronic course, higher total eczema score and more frequent distribution in the head-neck-face regions (196).

B- Staph aureus has itch inducing mechanism

Staphylococcal exotoxins can lead to IL-31 expression by T cells (170), which is a known mediator of itch. Staph can also mediate itch through serine protease activation of PAR-2 receptor (197).

Scalp Sebum has both itch protective and itch inducing mechanisms

The scalp is a sebum rich zone that is even richer than the face. Human sebaceous glands secrete a lipid mixture (sebum) containing squalene, wax esters, cholesterol esters, triglycerides, and free cholesterol. On the surface of the skin, triglycerides produce FFAs by catalytic reactions in the presence of bacterial hydrolases (198). Some of these FFAs are highly irritating to the skin.

Skin Surface lipid chemical composition can be severely altered in different skin diseases. This is the case of AD, seborrheic dermatitis and psoriasis (199-202).

On the contrary, Sebum content was significantly lower in people with sensitive scalp to hair dyes compared to non-sensitive group (203). FFAs in the skin surface lipids function as a barrier to diseases caused by bacteria and fungi and keep the surface acidity constant an important factor in inhibiting proteases and cathepsins (204,205).

There is marked individual and anatomical variability in the amount and composition of sebum in human skin (198,206,207). The total amounts of FFAs were greatest in the scalp (198).

Scalp Stratum corneum has itch protective measures

Stratum corneum of the scalp skin is functionally distinct from that of the face and extremities. The water barrier function of the scalp stratum corneum was almost comparable to that of the volar forearm, but was far better than that of facial skin. Hydration of the scalp skin surface was markedly higher than that of facial skin and volar forearm. These characteristics seem to be dependent, at least to some extent, on the amount of sebum-derived skin surface lipids because these were abundant on the scalp skin (208). This may have a protective measure to reduce scalp itch in healthy skin as good barrier function prevents signaling of exogenous factors such as soaps, bacterial infections and other irritants from inducing itch.

Conclusion

Scalp itch continues to be a major symptom for dermatologic patients. The scalp has a complex neuroanatomy with abundance of sensory neural end organs in the pilosebacous unit. Because ‘itchy scalp’ is a common complaint with disparate origins; namely dermatologic, neuropathic, systemic and psychogenic; dissecting these neural circuits, their anatomical and physiologic role in itch is of prime importance. Understanding the unique features of itch circuit in the scalp is key to development of effective therapies. Table 2 summarizes future therapeutic targets for interventions for scalp itch. A highly focused hypothesis-driven approach must be applied when trying to parse out mechanisms of scalp pruritus

Table 2.

Novel therapeutic targets in scalp pruritus*

Pruritic mediator Scalp itch target Therapy

Proteinase-activated
receptor 2
AD, chronic dry
skin, pruritus of
elderly, chronic
folliculitis, and acne-
form related itch in
scalp.
Tetracycline and its derivatives: doxycycline,
minocycline.
PAR-2 antibodies [such as SAM-11 (Santa Cruz)
and P2pal-2135]

PAR-2 antagonists [such as FSLLRY (Peptides
International), ENMD-106836]
Endogenous proteases:
- Serine proteases (mast
cell tryptase and kallikreins).
-chronic folliculitis,
and pruritus of
elderly.
- Nafamostat mesilate and camostat mesilate
- Cysteine proteases
(Cathepsin S)
-AD, and pruritus of
elderly.
- Cathepsin S inhibitor (E-64)
Transient receptor potential
vanilloid- type 1
neuropathic itch,
AD, prurigo
nodularis, lichen
simplex chronicus,
and psoriasis.
Topical capsaicin, Topical tacrolimus
Histamine 1 and 4 receptors AD, psoriasis, and
seborrhoeic
dermatitis.
Anti-histamines
Mu-opioid receptor systemic pruritus,
intractable pruritus,
AD, and prurigo
nodularis.
Mu-opioid receptor antagonists such as naloxone,
naltrexone, 1% naltrexone cream, nalmefene,
Butorphanol, methylnaltrexone
Kappa-opioid receptor systemic pruritus,
intractable pruritus,
and acute opioid
induced pruritus.
Kappa-opioid receptor agonists such as
Nalfurafine, bremazocine, GR 89696,
Butorphanol, topical liposomal butorphanol
preparation, ICI 204,448 (Tocris Bioscience),
Asimadoline (EMD-61753), SA14867 (Santen
Pharmaceutical Co.)
Interleukin-31 AD, prurigo
nodularis, lichen
simplex chronicus,
staph folliculitis, and
lichen amyloidosis
in scalp.
IL-31 antibody
Neurokinin Receptor AD, prurigo
nodularis, pruritus
of malignancy, and
chronic refractory
pruritus.
NK1R-antagonist (Aprepitant)
Cannabinoids AD, and
neuropathic itch.
Topical cannabinoid receptor agonists
*

Source: with modification from (209)

Acknowledgements

Dr Yosipovitch is funded by NIH grant RO-1AR55902-3.

Dr Yosipovitch designed the paper. Dr BenSaif wrote the paper and analyzed the data with Dr Yosipovitch. Dr Ericson provided images and analyzed the data. All authors fully read the final draft and provided their approval.

FUNDING SOURCES: Gil Yosipovitch is funded by NIH Ro-11R01AR055902-01A1.

ABBREVIATIONS

AD

Atopic dermatitis

BDNF

Brain-derived neurotrophic factor

CB

Cannabinoid receptor

CGRP

Calcitonin gene-related peptide

DOR

Delta-opioid receptor

DP

Follicular dermal papillae

eCB

Endogenous cannibinoids

ECP

Eosinophil cationic protein

ET

Endothelin

FFA

Free fatty acids

GRPR

Gastrin-related peptide receptor

HF

Hair follicle

IL

Interleukin

IRS

Inner root sheath

KOR

Kappa-opioid receptor

MC

Mast cell

MOR

Mu-opioid receptor

Mrgpr

Mas-related G protein-coupled receptor

NF

Nerve fiber

NGF

Nerve growth factor

NK1R

Neurokinin-1 receptor

NT-3

Neurotrophin 3

NT-4

Neurotrophin 4

ORS

Outer root sheath

PAR-2

Proteinase activating receptor 2

PGD2

Prostaglandin D2

PHI

Post herpetic neuralgic itch

PHN

Post herpetic neuralgia

SP

Substance P

TrkA

High-affinity NGF receptor

TRPV1

Transient receptor potential vanilloid-type 1

TXA2

Thromboxane A2

Footnotes

CONFLICTS OF INTEREST: None of the authors has conflicts of interest to declare.

The authors state no conflict of interest

References

  • 1.Bernhard JD. The itchy scalp and other pruritic curiosities. Semin Dermatol. 1995;14:326–9. doi: 10.1016/s1085-5629(05)80056-2. [DOI] [PubMed] [Google Scholar]
  • 2.Weisshaar E, Dalgard F. Epidemiology of itch: adding to the burden of skin morbidity. Acta Derm Venereol. 2009;89:339–50. doi: 10.2340/00015555-0662. [DOI] [PubMed] [Google Scholar]
  • 3.Misery L, Sibaud V, Ambronati M, Macy G, Boussetta S, Taieb C. Sensitive scalp: does this condition exist? An epidemiological study. Contact Dermatitis. 2008;58:234–8. doi: 10.1111/j.1600-0536.2007.01288.x. [DOI] [PubMed] [Google Scholar]
  • 4.T-J Goon A, Yosipovitch G, Chan YH, Goh CL. Clinical characteristics of generalized idiopathic pruritus in patients from a tertiary referral center in Singapore. Int J Dermatol. 2007;46:1023–6. doi: 10.1111/j.1365-4632.2007.03152.x. [DOI] [PubMed] [Google Scholar]
  • 5.Ferm I, Sterner M, Wallengren J. Somatic and psychiatric comorbidity in patients with chronic pruritus. Acta Derm Venereol. 2010;90:395–400. doi: 10.2340/00015555-0864. [DOI] [PubMed] [Google Scholar]
  • 6.Ständer S, Weisshaar E, Mettang T, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol. 2007;87:291–4. doi: 10.2340/00015555-0305. [DOI] [PubMed] [Google Scholar]
  • 7.O’Neill JL, Chan Y-H, Rapp SR, Yosipovitch G. Preview of article: Differences in Itch Characteristics Between Psoriasis and Atopic Dermatitis Patients: Results of a Web-based Questionnaire. Acta Derm Venereol. 2011 Apr 29; doi: 10.2340/00015555-1126. DOI: 10.2340/00015555-1126. [Epub ahead of print] [DOI] [PubMed] [Google Scholar]
  • 8.Chieregato C, Zini A, Barba A, Magnanini M, Rosina P. Lichen planopilaris: report of 30 cases and review of the literature. Int J Dermatol. 2003;42:342–5. doi: 10.1046/j.1365-4362.2003.01695.x. [DOI] [PubMed] [Google Scholar]
  • 9.Cevasco NC, Bergfeld WF, Remzi BK, de Knott HR. A case-series of 29 patients with lichen planopilaris: The Cleveland Clinic foundation experience on evaluation, diagnosis, and treatment. J Am Acad Dermatol. 2007;57:47–53. doi: 10.1016/j.jaad.2007.01.011. [DOI] [PubMed] [Google Scholar]
  • 10.Samrao A, Chew AL, Price V. Frontal fibrosing alopecia: a clinical review of 36 patients. Br J Dermatol. 2010;163:1296–300. doi: 10.1111/j.1365-2133.2010.09965.x. [DOI] [PubMed] [Google Scholar]
  • 11.Whiting DA, Olsen EA. Central centrifugal cicatricial alopecia. Dermatol Ther. 2008;21:268–78. doi: 10.1111/j.1529-8019.2008.00209.x. [DOI] [PubMed] [Google Scholar]
  • 12.Abdel-Hamid IA, Agha SA, Moustafa YM, El-Labban AM. Pityriasis amiantacea: a clinical and etiopathologic study of 85 patients. Int J Dermatol. 2003;42:260–4. doi: 10.1046/j.1365-4362.2003.01755.x. [DOI] [PubMed] [Google Scholar]
  • 13.Otberg N, Kang H, Alzolibani AA, Shapiro J. Folliculitis decalvans. Dermatol Ther. 2008;21:238–44. doi: 10.1111/j.1529-8019.2008.00204.x. [DOI] [PubMed] [Google Scholar]
  • 14.Chen AY, Janik MP, Moad JC, Rubin MB. Multiple papules and nodules of the scalp. Angiolymphoid hyperplasia with eosinophilia. Arch Dermatol. 2010;146:911–6. doi: 10.1001/archdermatol.2010.173-a. [DOI] [PubMed] [Google Scholar]
  • 15.Scribner M. Diabetes and pruritus of the scalp. JAMA. 1977;237:1559. [PubMed] [Google Scholar]
  • 16.Hoss D, Segal S. Scalp dysesthesia. Arch Dermatol. 1998;134:327–30. doi: 10.1001/archderm.134.3.327. [DOI] [PubMed] [Google Scholar]
  • 17.Oaklander AL. Neuropathic itch. Semin Cutan Med Surg. 2011;30:87–9. doi: 10.1016/j.sder.2011.04.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Oaklander AL. Neuropathic pruritus following Wallenberg syndrome. Neurology. 2009;73:1605. doi: 10.1212/WNL.0b013e3181bd6c10. [DOI] [PubMed] [Google Scholar]
  • 19.Darken RS, Bogitch R, Leonard J, et al. Brainstem glioma presenting as pruritus in children with neurofibromatosis-1. J Pediatr Hematol Oncol. 2009;31:972–6. doi: 10.1097/MPH.0b013e3181b8701f. [DOI] [PubMed] [Google Scholar]
  • 20.Tilstra JS, Prevost N, Khera P, English JC., 3rd Scalp dermatomyositis revisited. Arch Dermatol. 2009;145:1062–3. doi: 10.1001/archdermatol.2009.194. [DOI] [PubMed] [Google Scholar]
  • 21.Shirani Z, Kucenic MJ, Carroll CL, et al. Pruritus in adult dermatomyositis. Clin Exp Dermatol. 2004;29:273–6. doi: 10.1111/j.1365-2230.2004.01510.x. [DOI] [PubMed] [Google Scholar]
  • 22.McCauley CS, Blumenthal MS. Dobutamine and pruritus of the scalp. Ann Intern Med. 1986;105:966. doi: 10.7326/0003-4819-105-6-966_1. [DOI] [PubMed] [Google Scholar]
  • 23.Grosshans E, Asch PH. Eosinophilic arteritis of the scalp. Ann Dermatol Venereol. 2001;128:545–8. [PubMed] [Google Scholar]
  • 24.Piérard-Franchimont C, Hermanns JF, Degreef H, Piérard GE. From axioms to new insights into dandruff. Dermatology. 2000;200:93–8. doi: 10.1159/000018337. [DOI] [PubMed] [Google Scholar]
  • 25.DeAngelis YM, Gemmer CM, Kaczvinsky JR, Kenneally DC, Schwartz JR, Dawson TL., Jr Three etiologic facets of dandruff and seborrheic dermatitis: Malassezia fungi, sebaceous lipids, and individual sensitivity. J Investig Dermatol Symp Proc. 2005;10:295–7. doi: 10.1111/j.1087-0024.2005.10119.x. [DOI] [PubMed] [Google Scholar]
  • 26.Gloor M. Skin surface lipids. Physiologic function – influence of various dermatoses – pharmacologically induced changes. Hautarzt. 1975;26:6–10. [PubMed] [Google Scholar]
  • 27.Kesavan S, Holland KT, Ingham E. The effects of lipid extraction on the immunomodulatory activity of Malassezia species in vitro. Med Mycol. 2000;38:239–47. doi: 10.1080/mmy.38.3.239.247. [DOI] [PubMed] [Google Scholar]
  • 28.Kerr K, Schwartz JR, Filloon T, et al. Scalp Stratum Corneum Histamine Levels: Novel Sampling Method Reveals Association with Itch Resolution in Dandruff/Seborrhoeic Dermatitis Treatment. Acta Derm Venereol. 2011 Feb 21; doi: 10.2340/00015555-1073. doi: 10.2340/00015555-1073. [Epub ahead of print] [DOI] [PubMed] [Google Scholar]
  • 29.Prignano F, Ricceri F, Pescitelli L, Lotti T. Itch in psoriasis: epidemiology, clinical aspects and treatment options. Clin Cosmet Investig Dermatol. 2009;19:9–13. doi: 10.2147/ccid.s4465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Assouly P, Reygagne P. Lichen planopilaris: update on diagnosis and treatment. Semin Cutan Med Surg. 2009;28:3–10. doi: 10.1016/j.sder.2008.12.006. [DOI] [PubMed] [Google Scholar]
  • 31.McMichael AJ. Hair and scalp disorders in ethnic populations. Dermatol Clin. 2003;21:629–44. doi: 10.1016/s0733-8635(03)00077-9. [DOI] [PubMed] [Google Scholar]
  • 32.Oaklander AL, Cohen SP, Raju SV. Intractable postherpetic itch and cutaneous deafferentation after facial shingles. Pain. 2002;96:9–12. doi: 10.1016/s0304-3959(01)00400-6. [DOI] [PubMed] [Google Scholar]
  • 33.Oaklander AL, Bowsher D, Galer B, Haanpää M, Jensen MP. Herpes zoster itch: preliminary epidemiologic data. J Pain. 2003;4:338–43. doi: 10.1016/s1526-5900(03)00637-0. [DOI] [PubMed] [Google Scholar]
  • 34.Oaklander AL. Mechanisms of pain and itch caused by herpes zoster (shingles) J Pain. 2008;9:S10–8. doi: 10.1016/j.jpain.2007.10.003. [DOI] [PubMed] [Google Scholar]
  • 35.Ross SE, Mardinly AR, McCord AE, et al. Loss of inhibitory interneurons in the dorsal spinal cord and elevated itch in Bhlhb5 mutant mice. Neuron. 2010;25(65):886–98. doi: 10.1016/j.neuron.2010.02.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Cevikbas F, Steinhoff M, Ikoma A. Role of Spinal Neurotransmitter Receptors in Itch: New Insights into Therapies and Drug Development. CNS Neurosci Ther. 2010 Oct 15; doi: 10.1111/j.1755-5949.2010.00201.x. doi: 10.1111/j.1755-5949.2010.00201.x. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Farage MA. Perceptions of sensitive skin: changes in perceived severity and associations with environmental causes. Contact Dermatitis. 2008;59:226–32. doi: 10.1111/j.1600-0536.2008.01398.x. [DOI] [PubMed] [Google Scholar]
  • 38.Muizzuddin N, Marenus KD, Maes DH. Factors defining sensitive skin and its treatment. Am J Contact Dermat. 1998;9:170–5. [PubMed] [Google Scholar]
  • 39.Saint-Martory C, Roguedas-Contios AM, Sibaud V, Degouy A, Schmitt AM, Misery L. Sensitive skin is not limited to the face. Br J Dermatol. 2008;158:130–3. doi: 10.1111/j.1365-2133.2007.08280.x. [DOI] [PubMed] [Google Scholar]
  • 40.Misery L, Rahhali N, Ambonati M, et al. Evaluation of sensitive scalp severity and symptomatology by using a new score. J Eur Acad Dermatol Venereol. 2011 Jan 17; doi: 10.1111/j.1468-3083.2010.03968.x. doi: 10.1111/j.1468-3083.2010.03968.x. [Epub ahead of print] [DOI] [PubMed] [Google Scholar]
  • 41.Hendrix S, Picker B, Liezmann C, Peters EM. Skin and hair follicle innervation in experimental models: a guide for the exact and reproducible evaluation of neuronal plasticity. Exp Dermatol. 2008;17:214–27. doi: 10.1111/j.1600-0625.2007.00653.x. [DOI] [PubMed] [Google Scholar]
  • 42.Hordinsky MK, Ericson M. Hair innervation and vasculature. Exp Dermatol. 1999;8:314. [PubMed] [Google Scholar]
  • 43.Halata Z. Sensory innervation of the hairy skin (light-and electronmicroscopic study) J Invest Dermatol. 1993;101:75S. doi: 10.1111/1523-1747.ep12362877. [DOI] [PubMed] [Google Scholar]
  • 44.Hashimoto K, Ito M, Suzuki Y. Innervation and vasculature of the hair follicle. In: Orfanos CE, Happle R, editors. Hair and Hair Diseases. Springer-Verlag; Berlin: 1990. p. 117. [Google Scholar]
  • 45.Peters EM, Botchkarev VA, Botchkareva NV, Tobin DJ, Paus R. Hair cycle-associated remodeling of the peptidergic innervation of murine skin, and hair growth modulation by neuropeptides. J Invest Dermatol. 2001;116:236–45. doi: 10.1046/j.1523-1747.2001.01232.x. [DOI] [PubMed] [Google Scholar]
  • 46.Peters EM, Ericson ME, Hosoi J, et al. Neuropeptide control mechanisms in cutaneous biology: physiological and clinical significance. J Invest Dermatol. 2006;126:1937–47. doi: 10.1038/sj.jid.5700429. [DOI] [PubMed] [Google Scholar]
  • 47.Liu X, Zhang Y, Liao J. Regional differences in capillary density of children’s skin--an enzyme histochemical and stereological study. Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi. 1998;14:448–51. [PubMed] [Google Scholar]
  • 48.Pasyk KA, Thomas SV, Hassett CA, Cherry GW, Faller R. Regional differences in capillary density of the normal human dermis. Plast Reconstr Surg. 1989;83:939–45. discussion 946-7. [PubMed] [Google Scholar]
  • 49.Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest. 2001;107:409–17. doi: 10.1172/JCI11317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Namer B, Carr R, Johanek LM, Schmelz M, Handwerker HO, Ringkamp M. Separate peripheral pathways for pruritus in man. J Neurophysiol. 2008;100:2062–9. doi: 10.1152/jn.90482.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Ständer S, Raap U, Weisshaar E, et al. Pathogenesis of pruritus. J Dtsch Dermatol Ges. 2011;9:456–63. doi: 10.1111/j.1610-0387.2011.07585.x. [DOI] [PubMed] [Google Scholar]
  • 52.Johansson O, Wang L, Hilliges M, Liang Y. Intraepidermal nerves in human skin: PGP 9.5 immunohistochemistry with special reference to the nerve density in skin from different body regions. J Peripher Nerv Syst. 1999;4:43–52. [PubMed] [Google Scholar]
  • 53.Arthur RP, Shelley WB. The innervation of human epidermis. J Invest Dermatol. 1959;32:397–411. doi: 10.1038/jid.1959.69. [DOI] [PubMed] [Google Scholar]
  • 54.Truini A, Leone C, Di Stefano G, et al. Topographical distribution of warmth, burning and itch sensations in healthy humans. Neurosci Lett. 2011;494:165–8. doi: 10.1016/j.neulet.2011.03.004. [DOI] [PubMed] [Google Scholar]
  • 55.Rukwied R, Zeck S, Schmelz M, McGlone F. Sensitivity of human scalp skin to pruritic stimuli investigated by intradermal microdialysis in vivo. J Am Acad Dermatol. 2002;47:245–50. doi: 10.1067/mjd.2002.120461. [DOI] [PubMed] [Google Scholar]
  • 56.Steinhoff M, Neisius U, Ikoma A, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci. 2003;23:6176–80. doi: 10.1523/JNEUROSCI.23-15-06176.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Shelley W, Arthur R. The neurohistology and neurophysiology of the itch sensation in man. Arch Dermatol. 1957;76:296–323. doi: 10.1001/archderm.1957.01550210020004. [DOI] [PubMed] [Google Scholar]
  • 58.Ozawa M, Tsuchiyama K, Gomi R, Kurosaki F, Kawamoto Y, Aiba S. Neuroselective transcutaneous electric stimulation reveals body area-specific differences in itch perception. J Am Acad Dermatol. 2006;55:996–1002. doi: 10.1016/j.jaad.2006.08.032. [DOI] [PubMed] [Google Scholar]
  • 59.Essick G, Guest S, Martinez E, Chen C, McGlone F. Site-dependent and subject-related variations in perioral thermal sensitivity. Somatosens Mot Res. 2004;21:159–75. doi: 10.1080/08990220400012414. [DOI] [PubMed] [Google Scholar]
  • 60.Stevens JC, Marks LE, Simonson DC. Regional sensitivity and spatial summation in the warmth sense. Physiol Behav. 1974;13:825–36. doi: 10.1016/0031-9384(74)90269-8. [DOI] [PubMed] [Google Scholar]
  • 61.Stevens JC, Marks LE. Spatial summation of cold. Physiol Behav. 1979;22:541–7. doi: 10.1016/0031-9384(79)90023-4. [DOI] [PubMed] [Google Scholar]
  • 62.Price DD, McHaffie JG, Larson MA. Spatial summation of heat-induced pain: influence of stimulus area and spatial separation of stimuli on perceived pain sensation intensity and unpleasantness. J Neurophysiol. 1989;62:1270–9. doi: 10.1152/jn.1989.62.6.1270. [DOI] [PubMed] [Google Scholar]
  • 63.Murray FS, Hagan BC. Pain threshold and tolerance of hands and feet. J Comp Physiol Psychol. 1973;84:639–43. doi: 10.1037/h0034836. [DOI] [PubMed] [Google Scholar]
  • 64.Yamaura K, Oda M, Suwa E, Suzuki M, Sato H, Ueno K. Expression of histamine H4 receptor in human epidermal tissues and attenuation of experimental pruritus using H4 receptor antagonist. J Toxicol Sci. 2009;34:427–31. doi: 10.2131/jts.34.427. [DOI] [PubMed] [Google Scholar]
  • 65.Cowden JM, Zhang M, Dunford PJ, Thurmond RL. The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. J Invest Dermatol. 2010;130:1023–33. doi: 10.1038/jid.2009.358. [DOI] [PubMed] [Google Scholar]
  • 66.Sugimoto Y, Iba Y, Nakamura Y, Kayasuga R, Kamei C. Pruritus-associated response mediated by cutaneous histamine H3 receptors. Clin Exp Allergy. 2004;34:456–9. doi: 10.1111/j.1365-2222.2004.01876.x. [DOI] [PubMed] [Google Scholar]
  • 67.Paus R, Maurer M, Slominski A, Czarnetzki BM. Mast cell involvement in murine hair growth. Dev Biol. 1994;163:230–40. doi: 10.1006/dbio.1994.1139. [DOI] [PubMed] [Google Scholar]
  • 68.Maurer M, Fischer E, Handjiski B, et al. Activated skin mast cells are involved in murine hair follicle regression (catagen) Lab Invest. 1997;77:319–32. [PubMed] [Google Scholar]
  • 69.Moretti G, Rebora A, Giacometti C, Boido V, Rampini E, Cipriani C. The quantitative behavior of cutaneous histamine and mast cells in the hair cycles of rats. J Invest Dermatol. 1966;46:231–9. doi: 10.1038/jid.1966.36. [DOI] [PubMed] [Google Scholar]
  • 70.Stenn KS, Paus R. Controls of hair follicle cycling. Physiol Rev. 2001;81:449–94. doi: 10.1152/physrev.2001.81.1.449. [DOI] [PubMed] [Google Scholar]
  • 71.Damsgaard TE, Olesen AB, Sorensen FB, Thestrup-Pedersen K, Schiotz PO. Mast cells and atopic dermatitis. Stereological quantification of mast cells in atopic dermatitis and normal human skin. Arch Dermatol Res. 1997;289:256–60. doi: 10.1007/s004030050189. [DOI] [PubMed] [Google Scholar]
  • 72.Nakamura M, Toyoda M, Morohashi M. Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol. 2003;149:718–30. doi: 10.1046/j.1365-2133.2003.05586.x. [DOI] [PubMed] [Google Scholar]
  • 73.Steinhoff M, Vergnolle N, Young SH, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med. 2000;6:151–8. doi: 10.1038/72247. [DOI] [PubMed] [Google Scholar]
  • 74.Paus R, Schmelz M, Bíró T, Steinhoff M. Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest. 2006;116:1174–86. doi: 10.1172/JCI28553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Reddy VB, Shimada SG, Sikand P, Lamotte RH, Lerner EA. Cathepsin S elicits itch and signals via protease-activated receptors. J Invest Dermatol. 2010;130:1468. doi: 10.1038/jid.2009.430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Steinhoff M, Buddenkotte J, Shpacovitch V, et al. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev. 2005;26:1–43. doi: 10.1210/er.2003-0025. [DOI] [PubMed] [Google Scholar]
  • 77.Amadesi S, Nie J, Vergnolle N, et al. Protease-activated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia. J Neurosci. 2004;24:4300–12. doi: 10.1523/JNEUROSCI.5679-03.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Rattenholl A, Steinhoff M. Proteinase-activated receptor-2 in the skin: receptor expression, activation and function during health and disease. Drug News Perspect. 2008;21:369–81. doi: 10.1358/dnp.2008.21.7.1255294. [DOI] [PubMed] [Google Scholar]
  • 79.Steinhoff M, Corvera CU, Thoma MS, et al. Proteinase-activated receptor-2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase. Exp Dermatol. 1999;8:282–94. doi: 10.1111/j.1600-0625.1999.tb00383.x. [DOI] [PubMed] [Google Scholar]
  • 80.Eissa A, Diamandis EP. Human tissue kallikreins as promiscuous modulators of homeostatic skin barrier functions. Biol Chem. 2008;389:669–80. doi: 10.1515/BC.2008.079. [DOI] [PubMed] [Google Scholar]
  • 81.Lee SE, Jeong SK, Lee SH. Protease and protease-activated receptor-2 signaling in the pathogenesis of atopic dermatitis. Yonsei Med J. 2010;51:808–22. doi: 10.3349/ymj.2010.51.6.808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Frateschi S, Camerer E, Crisante G, et al. PAR2 absence completely rescues inflammation and ichthyosis caused by altered CAP1/Prss8 expression in mouse skin. Nat Commun. 2011;2:161. doi: 10.1038/ncomms1162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Ugawa S, Ueda T, Ishida Y, Nishigaki M, Shibata Y, Shimada S. Amiloride-blockable acid-sensing ion channels are leading acid sensors expressed in human nociceptors. J Clin Invest. 2002;110:1185–90. doi: 10.1172/JCI15709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Di Marzo V, Blumberg PM, Szallasi A. Endovanilloid signaling in pain. Curr Opin Neurobiol. 2002;12:372–9. doi: 10.1016/s0959-4388(02)00340-9. [DOI] [PubMed] [Google Scholar]
  • 85.Imamachi N, Park GH, Lee H, et al. TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms. Proc Natl Acad Sci U S A. 2009;106:11330–5. doi: 10.1073/pnas.0905605106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Bodó E, Kovács I, Telek A, et al. Vanilloid receptor-1 is widely expressed on various epithelial and mesenchymal cell types of human skin. J Invest Dermatol. 2004;123:410–3. doi: 10.1111/j.0022-202X.2004.23209.x. [DOI] [PubMed] [Google Scholar]
  • 87.Ständer S, Moormann C, Schumacher M, et al. Expression of vanilloid receptor subtype 1 in cutaneous sensory fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol. 2004;13:129–39. doi: 10.1111/j.0906-6705.2004.0178.x. [DOI] [PubMed] [Google Scholar]
  • 88.Bodó E, Bíró T, Telek A, et al. A hot new twist to hair biology: involvement of vanilloid receptor-1 (VR1/TRPV1) signaling in human hair growth control. Am J Pathol. 2005;166(4):985–98. doi: 10.1016/S0002-9440(10)62320-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Maggi CV, Borsini F, Santicioli P. Cutaneous lesions in capsaicin pretreated rats. A trophic role of capsaicin-sensitive afferents? Naunyn-Schmiedebergs Arch Pharmacol. 1987;336:538–45. doi: 10.1007/BF00169311. [DOI] [PubMed] [Google Scholar]
  • 90.Patel KN, Liu Q, Meeker S, Undem BJ, Dong X. Pirt, a TRPV1 Modulator, Is Required for Histamine-Dependent and -Independent Itch. PLoS One. 2011;6:e20559. doi: 10.1371/journal.pone.0020559. Epub 2011 May 31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Pereira U, Boulais N, Lebonvallet N, Pennec JP, Dorange G, Misery L. Mechanisms of the sensory effects of tacrolimus on the skin. Br J Dermatol. 2010;163:70–7. doi: 10.1111/j.1365-2133.2010.09757.x. [DOI] [PubMed] [Google Scholar]
  • 92.Yoshioka T, Imura K, Asakawa M, et al. Impact of the Gly573Ser substitution in TRPV3 on the development of allergic and pruritic dermatitis in mice. Invest Dermatol. 2009;129:714–22. doi: 10.1038/jid.2008.245. [DOI] [PubMed] [Google Scholar]
  • 93.Radtke C, Sinis N, Sauter M, et al. TRPV channel expression in human skin and possible role in thermally induced cell death. J Burn Care Res. 2011;32:150–9. doi: 10.1097/BCR.0b013e318203350c. [DOI] [PubMed] [Google Scholar]
  • 94.Facer P, Casula MA, Smith GD, et al. Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. BMC Neurol. 2007;7:11. doi: 10.1186/1471-2377-7-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Borbíró I, Lisztes E, Tóth BI, et al. Activation of Transient Receptor Potential Vanilloid-3 Inhibits Human Hair Growth. J Invest Dermatol. 2011 May 19; doi: 10.1038/jid.2011.122. Epub ahead of print. [DOI] [PubMed] [Google Scholar]
  • 96.Liu Q, Weng HJ, Patel KN, et al. The Distinct Roles of Two GPCRs, MrgprC11 and PAR2, in Itch and Hyperalgesia. Sci Signal. 2011;4:ra45. doi: 10.1126/scisignal.2001925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Liu Q, Tang Z, Surdenikova L, et al. Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus. Cell. 2009;139:1353–65. doi: 10.1016/j.cell.2009.11.034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Dong X, Han S, Zylka MJ, Simon MI, Anderson DJ. A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell. 2001;106:619–32. doi: 10.1016/s0092-8674(01)00483-4. [DOI] [PubMed] [Google Scholar]
  • 99.Lembo PM, Grazzini E, Groblewski T, et al. Proenkephalin A gene products activate a new family of sensory neuron--specific GPCRs. Nat Neurosci. 2002;5:201–9. doi: 10.1038/nn815. [DOI] [PubMed] [Google Scholar]
  • 100.Han SK, Dong X, Hwang JI, Zylka MJ, Anderson DJ, Simon MI. Orphan G protein-coupled receptors MrgA1 and MrgC11 are distinctively activated by RF-amide-related peptides through the Galpha q/11 pathway. Proc Natl Acad Sci U S A. 2002;99:14740–5. doi: 10.1073/pnas.192565799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Sikand P, Dong X, Lamotte RH. BAM8-22 Peptide Produces Itch and Nociceptive Sensations in Humans Independent of Histamine Release. J Neurosci. 2011;31:7563–7. doi: 10.1523/JNEUROSCI.1192-11.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Wilson SR, Gerhold KA, Bifolck-Fisher A, et al. TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch. Nat Neurosci. 2011;14:595–602. doi: 10.1038/nn.2789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Bigliardi PL, Tobin DJ, Gaveriaux-Ruff C, Bigliardi-Qi M. Opioids and the skin--where do we stand? Exp Dermatol. 2009;18:424–30. doi: 10.1111/j.1600-0625.2009.00844.x. [DOI] [PubMed] [Google Scholar]
  • 104.Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol. 2010;63:680–8. doi: 10.1016/j.jaad.2009.08.052. [DOI] [PubMed] [Google Scholar]
  • 105.Ständer S, Schmelz M. Chronic itch and painesimilarities and differences. Eur J Pain. 2006;10:473–8. doi: 10.1016/j.ejpain.2006.03.005. [DOI] [PubMed] [Google Scholar]
  • 106.Andrew D, Craig AD. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci. 2001;4:72–7. doi: 10.1038/82924. [DOI] [PubMed] [Google Scholar]
  • 107.PG Atanassoff , Brull SJ, Zhang J, Greenquist K, Silverman DG, Lamotte RH. Enhancement of experimental pruritus and mechanically evoked dysesthesiae with local anesthesia. Somatosens Mot Res. 1999;16:291–8. doi: 10.1080/08990229970357. [DOI] [PubMed] [Google Scholar]
  • 108.Bíró T, Tóth BI, y R, Dobrosi N, Géczy T, Paus R. TRP channels as novel players in the pathogenesis and therapy of itch. Biochim Biophys Acta. 2007;1772:1004–21. doi: 10.1016/j.bbadis.2007.03.002. [DOI] [PubMed] [Google Scholar]
  • 109.Reich A, Szepietowski JC. Opioid-induced pruritus: an update. Clin Exp Dermatol. 2010;35:2–6. doi: 10.1111/j.1365-2230.2009.03463.x. [DOI] [PubMed] [Google Scholar]
  • 110.Swegle JM, Logemann C. Management of common opioid induced adverse effects. Am Pham Phys. 2006;74:1347–54. [PubMed] [Google Scholar]
  • 111.Szarvas S, Harmon D, Murphy D. Neuraxial opioid-induced pruritus: a review. J Clin Anesth. 2003;15:234–9. doi: 10.1016/s0952-8180(02)00501-9. [DOI] [PubMed] [Google Scholar]
  • 112.Thomas DA, Williams GM, Iwata K, Kenshalo DR, Jr, Dubner R. The medullary dorsal horn. A site of action of morphine in producing facial scratching in monkeys. Anesthesiology. 1993;79:548–54. [PubMed] [Google Scholar]
  • 113.Slominski A, Wortsman J, Mazurkiewicz JE, et al. Detection of proopiomelanocortin-derived antigens in normal and pathologic human skin. J Lab Clin Med. 1993;122:658–66. [PubMed] [Google Scholar]
  • 114.Tominaga M, Ogawa H, Takamori K. Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J Invest Dermatol. 2007;127:2228–35. doi: 10.1038/sj.jid.5700942. [DOI] [PubMed] [Google Scholar]
  • 115.Heyer G, Groene D, Martus P. Efficacy of naltrexone on acetylcholine-induced alloknesis in atopic eczema. Exp Dermatol. 2002;11:448–55. doi: 10.1034/j.1600-0625.2002.110508.x. [DOI] [PubMed] [Google Scholar]
  • 116.Brune A, Metze D, Luger TA, Ständer S. Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients. Hautarzt. 2004;55:1130–6. doi: 10.1007/s00105-004-0802-8. [DOI] [PubMed] [Google Scholar]
  • 117.Wikström B, Gellert R, Ladefoged SD, et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol. 2005;16:3742–7. doi: 10.1681/ASN.2005020152. [DOI] [PubMed] [Google Scholar]
  • 118.Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant. 2010;25:1251–7. doi: 10.1093/ndt/gfp588. [DOI] [PubMed] [Google Scholar]
  • 119.Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol. 2006;54:527–31. doi: 10.1016/j.jaad.2005.12.010. [DOI] [PubMed] [Google Scholar]
  • 120.Bíró T, Tóth BI, Haskó G, Paus R, Pacher P. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci. 2009;30:411–20. doi: 10.1016/j.tips.2009.05.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Ständer S, Schmelz M, Metze D, Luger T, Rukwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci. 2005;38:177–88. doi: 10.1016/j.jdermsci.2005.01.007. [DOI] [PubMed] [Google Scholar]
  • 122.Eedy DJ, Shaw C, Johnston CF, Buchanan KD. The regional distribution of neuropeptides in human skin as assessed by radioimmunoassay and high-performance liquid chromatography. Clin Exp Dermatol. 1994;19:463–72. doi: 10.1111/j.1365-2230.1994.tb01248.x. [DOI] [PubMed] [Google Scholar]
  • 123.Peters EM, Liotiri S, Bodóq E, et al. Probing the effects of stress mediators on the human hair follicle: substance P holds central position. Am J Pathol. 2007;171:1872–86. doi: 10.2353/ajpath.2007.061206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 124.Paus R, Heinzelmann T, Schultz KD, Furkert J, Fechner K, Czarnetzki BM. Hair growth induction by substance P. Lab Invest. 1994;71:134–40. [PubMed] [Google Scholar]
  • 125.Arck PC, Handjiski B, Peters EMJ, et al. Stress inhibits hair growth in mice by induction of premature catagen development and deleterious perifollicular inflammatory events via neuropeptide substance P-dependent pathways. Am J Pathol. 2003;162:803–14. doi: 10.1016/S0002-9440(10)63877-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126.Arck PC, Handjiski B, Kuhlmei A, et al. Mast cell deficient and neurokinin-1 receptor knockout mice are protected from stress-induced hair growth inhibition. J Mol Med. 2005;83:386–96. doi: 10.1007/s00109-004-0627-z. [DOI] [PubMed] [Google Scholar]
  • 127.Arck P, Paus R. From the brain-skin connection: the neuroendocrine-immune misalliance of stress and itch. Neuroimmunomodulation. 2006;13:347–56. doi: 10.1159/000104863. [DOI] [PubMed] [Google Scholar]
  • 128.Stander S, Gunzer M, Metze D, Luger T, Steinhoff M. Localization of micro-opioid receptor 1A on sensory NFs in human skin. Regul Pept. 2002;110:75–83. doi: 10.1016/s0167-0115(02)00159-3. [DOI] [PubMed] [Google Scholar]
  • 129.Buldyrev I, Tanner NM, Hsieh HY, Dodd EG, Nguyen LT, Balkowiec A. Calcitonin gene-related peptide enhances release of native brain-derived neurotrophic factor from trigeminal ganglion neurons. J Neurochem. 2006;99:1338–50. doi: 10.1111/j.1471-4159.2006.04161.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130.Eedy DJ. Neuropeptides in skin. Br J Dermatol. 1993;128:597–605. doi: 10.1111/j.1365-2133.1993.tb00252.x. [DOI] [PubMed] [Google Scholar]
  • 131.Salomon J, Baran E. The role of selected neuropeptides in pathogenesis of atopic dermatitis. J Eur Acad Dermatol Venereol. 2008;22:223–8. doi: 10.1111/j.1468-3083.2007.02399.x. [DOI] [PubMed] [Google Scholar]
  • 132.Chang SE, Han SS, Jung HJ, Choi JH. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol. 2007;156:1272–7. doi: 10.1111/j.1365-2133.2007.07935.x. [DOI] [PubMed] [Google Scholar]
  • 133.Wiśnicka B, Szepietowski JC, Reich A, Orda A. Histamine, Substance P and Calcitonin Gene-Related Peptide Plasma Concentration and Pruritus in Patients Suffering from Psoriasis. Dermatol Psychosom. 2004;5:73–78. [Google Scholar]
  • 134.Reimann S, Luger T, Metze D. Topical administration of capsaicin in dermatology for treatment of itching and pain. Hautarzt. 2000;51:164–72. doi: 10.1007/s001050051014. [DOI] [PubMed] [Google Scholar]
  • 135.Ikoma A, Steinhoff M, Ständer S, Yosipovitch G, Schmelz M. The neurobiology of itch. Nat Rev Neurosci. 2006;7:535–47. doi: 10.1038/nrn1950. [DOI] [PubMed] [Google Scholar]
  • 136.Scuri M, Samsell L, Piedimonte G. The role of neurotrophins in inflammation and allergy. Inflamm Allergy Drug Targets. 2010;9:173–80. doi: 10.2174/187152810792231913. [DOI] [PubMed] [Google Scholar]
  • 137.Hon KL, Lam MC, Wong KY, Leung TF, Ng PC. Pathophysiology of nocturnal scratching in childhood atopic dermatitis: the role of brain-derived neurotrophic factor and substance P. Br J Dermatol. 2007;157:922–5. doi: 10.1111/j.1365-2133.2007.08149.x. [DOI] [PubMed] [Google Scholar]
  • 138.Grewe M, Vogelsang K, Ruzicka T, Stege H, Krutmann J. Neurotrophin-4 production by human epidermal keratinocytes: increased expression in atopic dermatitis. J Invest Dermatol. 2000;114:1108–12. doi: 10.1046/j.1523-1747.2000.00974.x. [DOI] [PubMed] [Google Scholar]
  • 139.Metz M, Botchkarev VA, Botchkareva NV, et al. Neurotrophin-3 regulates mast cell functions in neonatal mouse skin. Exp Dermatol. 2004;13:273–81. doi: 10.1111/j.0906-6705.2004.00115.x. [DOI] [PubMed] [Google Scholar]
  • 140.Verge VM, Richardson PM, Hallin Z, Hökfelt T. Differential influence of nerve growth factor on neuropeptide expression in vivo: a novel role in peptide suppression in adult sensory neurons. J Neurosci. 1995;15:2081–96. doi: 10.1523/JNEUROSCI.15-03-02081.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 141.Adly MA, Assaf HA, Nada EA, Soliman M, Hussein M. Expression of nerve growth factor and its high-affinity receptor, tyrosine kinase A proteins, in the human scalp skin. J Cutan Pathol. 2006;33:559–68. doi: 10.1111/j.1600-0560.2006.00443.x. [DOI] [PubMed] [Google Scholar]
  • 142.Peters EM, Hendrix S, Gölz G, Klapp BF, Arck PC, Paus R. Nerve growth factor and its precursor differentially regulate hair cycle progression in mice. J Histochem Cytochem. 2006;54:275–88. doi: 10.1369/jhc.4A6585.2005. [DOI] [PubMed] [Google Scholar]
  • 143.Peters EM, Arck PC, Paus R. Hair growth inhibition by psychoemotional stress: a mouse model for neural mechanisms in hair growth control. Exp Dermatol. 2006;15:1–13. doi: 10.1111/j.0906-6705.2005.00372.x. [DOI] [PubMed] [Google Scholar]
  • 144.Lang UE, Anders D, Danker-Hopfe H, Hellweg R. Measurement of nerve growth factor serum concentration in a psychologically stressful situation in men. Stress. 2004;7:39–42. doi: 10.1080/10253890310001638145. [DOI] [PubMed] [Google Scholar]
  • 145.EM Peters , Handjiski B, Kuhlmei A, et al. Neurogenic inflammation in stress-induced termination of murine hair growth is promoted by nerve growth factor. Am J Pathol. 2004;165:259–71. doi: 10.1016/S0002-9440(10)63294-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 146.Toyoda M, Nakamura M, Makino T, Hino T, Kagoura M, Morohashi M. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol. 2002;147:71–9. doi: 10.1046/j.1365-2133.2002.04803.x. [DOI] [PubMed] [Google Scholar]
  • 147.Groneberg DA, Serowka F, Peckenschneider N, et al. Gene expression and regulation of nerve growth factor in atopic dermatitis mast cells and the human mast cell line-1. J Neuroimmunol. 2005;161:87–92. doi: 10.1016/j.jneuroim.2004.12.019. [DOI] [PubMed] [Google Scholar]
  • 148.Tanaka A, Matsuda H. Expression of nerve growth factor in itchy skins of atopic NC/NgaTnd mice. J Vet Med Sci. 2005;67:915–9. doi: 10.1292/jvms.67.915. [DOI] [PubMed] [Google Scholar]
  • 149.Papoiu A, Wang H, Nattkemper L, et al. A Study of Serum Concentrations and Skin Levels of NGF in Atopic Dermatitis and Healthy Subject. Neuropeptides. doi: 10.1016/j.npep.2011.07.008. IN PRESS. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 150.Schulte-Herbrüggen O, yHolst R, von Elstermann M, Augustin M, Hellweg R. Clinical relevance of nerve growth factor serum levels in patients with atopic dermatitis and psoriasis. Int Arch Allergy Immunol. 2007;144:211–6. doi: 10.1159/000103994. [DOI] [PubMed] [Google Scholar]
  • 151.Raap U, Goltz C, Deneka N, et al. Brain-derived neurotrophic factor is increased in atopic dermatitis and modulates eosinophil functions compared with that seen in nonatopic subjects. J Allergy Clin Immunol. 2005;115:1268–75. doi: 10.1016/j.jaci.2005.02.007. [DOI] [PubMed] [Google Scholar]
  • 152.Urashima R, Mihara M. Cutaneous nerves in atopic dermatitis. A histological, immunohistochemical and electron microscopic study. Virchows Arch. 1998;432:363–70. doi: 10.1007/s004280050179. [DOI] [PubMed] [Google Scholar]
  • 153.Takano N, Sakurai T, Kurachi M. Effects of anti-nerve growth factor antibody on symptoms in the NC/Nga mouse, an atopic dermatitis model. J Pharmacol Sci. 2005;99:277–86. doi: 10.1254/jphs.fp0050564. [DOI] [PubMed] [Google Scholar]
  • 154.Takano N, Sakurai T, Ohashi Y, Kurachi M. Effects of high-affinity nerve growth factor receptor inhibitors on symptoms in the NC/Nga mouse atopic dermatitis model. Br J Dermatol. 2007;156:241–6. doi: 10.1111/j.1365-2133.2006.07636.x. [DOI] [PubMed] [Google Scholar]
  • 155.Kinkelin I, Mötzing S, Koltenzenburg M, Bröcker EB. Increase in NGF content and nerve fiber sprouting in human allergic contact eczema. Cell Tissue Res. 2000;302:31–7. doi: 10.1007/s004410000202. [DOI] [PubMed] [Google Scholar]
  • 156.Johansson O, Liang Y, Emtestam L. Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin -- an exploration of the cause of neurohyperplasia. Arch Dermatol Res. 2002;293:614–9. doi: 10.1007/s00403-001-0285-8. [DOI] [PubMed] [Google Scholar]
  • 157.Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature. 2007;448:700–3. doi: 10.1038/nature06029. [DOI] [PubMed] [Google Scholar]
  • 158.Sun YG, Zhao ZQ, Meng XL, Yin J, Liu XY, Chen ZF. Cellular basis of itch sensation. Science. 2009;325:1531–4. doi: 10.1126/science.1174868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 159.Staniek V, Misery L, Peguet-Navarro J, et al. Expression of gastrin-releasing peptide receptor in human skin. Acta Derm Venereol. 1996;76:282–6. doi: 10.2340/0001555576282286. [DOI] [PubMed] [Google Scholar]
  • 160.Terashi H, Kurata S, Tadokoro T, Sato H, Itami S. Immunohistochemical localization of gastrin releasing peptide in human skin and its proliferative effect and mRNA expression in cultured human keratinocytes, outer root sheath cells and fibroblasts. J Jpn P R S. 1996;16:373–80. [Google Scholar]
  • 161.Tominaga M, Ogawa H, Takamori K. Histological characterization of cutaneous nerve fibers containing gastrin-releasing peptide in NC/Nga mice: an atopic dermatitis model. J Invest Dermatol. 2009;129:2901–5. doi: 10.1038/jid.2009.188. [DOI] [PubMed] [Google Scholar]
  • 162.Katugampola R, Church MK, Clough GF. The neurogenic vasodilator response to endothelin-1: a study in human skin in vivo. Exp Physiol. 2000;85:839–46. [PubMed] [Google Scholar]
  • 163.Liang J, Kawamata T, Ji W. Molecular signaling of pruritus induced by endothelin-1 in mice. Exp Biol Med (Maywood) 2010;235:1300–5. doi: 10.1258/ebm.2010.010121. [DOI] [PubMed] [Google Scholar]
  • 164.Shrestha S, Gracias NG, Mujenda F, Khodorova A, Vasko MR, Strichartz GR. Local antinociception induced by endothelin-1 in the hairy skin of the rat’s back. J Pain. 2009;10:702–14. doi: 10.1016/j.jpain.2008.12.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 165.Darsow U, Scharein E, Bromm B, Ring J. Skin testing of the pruritogenic activity of histamine and cytokines (interleukin-2 and tumour necrosis factor-alpha) at the dermal-epidermal junction. Br J Dermatol. 1997;137:415–7. [PubMed] [Google Scholar]
  • 166.Martin HA, Murphy PR. Interleukin-2 activates a sub-population of cutaneous C-fibre polymodal nociceptors in the rat hairy skin. Arch Physiol Biochem. 1995;103:136–48. doi: 10.3109/13813459508996127. [DOI] [PubMed] [Google Scholar]
  • 167.Wahlgren CF, Tengvall Linder M, Hagermark O, Scheynius A. Itch and inflammation induced by intradermally injected interleukin-2 in atopic dermatitis patients and healthy subjects. Arch Dermatol Res. 1995;287:572–80. doi: 10.1007/BF00374079. [DOI] [PubMed] [Google Scholar]
  • 168.Yosipovitch G, Papoiu AD. What causes itch in atopic dermatitis? Curr Allergy Asthma Rep. 2008;8:306–11. doi: 10.1007/s11882-008-0049-z. [DOI] [PubMed] [Google Scholar]
  • 169.Gaspari AA, Lotze MT, Rosenberg SA, Stern JB, Katz SI. Dermatologic changes associated with interleukin 2 administration. JAMA. 1987;258:1624–9. [PubMed] [Google Scholar]
  • 170.Kasraie S, Niebuhr M, Werfel T. Interleukin (IL)-31 induces pro-inflammatory cytokines in human monocytes and macrophages following stimulation with staphylococcal exotoxins. Allergy. 2010;65:712–21. doi: 10.1111/j.1398-9995.2009.02255.x. [DOI] [PubMed] [Google Scholar]
  • 171.Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5:752–60. doi: 10.1038/ni1084. [DOI] [PubMed] [Google Scholar]
  • 172.Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117:411–7. doi: 10.1016/j.jaci.2005.10.033. [DOI] [PubMed] [Google Scholar]
  • 173.Takaoka A, Arai I, Sugimoto M, et al. Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis. Exp Dermatol. 2006;15:161–7. doi: 10.1111/j.1600-0625.2006.00405.x. [DOI] [PubMed] [Google Scholar]
  • 174.Kimata H, Lindley I. Detection of plasma interleukin-8 in atopic dermatitis. Arch Dis Child. 1994;70:119–22. doi: 10.1136/adc.70.2.119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 175.Hatano Y, Katagiri K, Takayasu S. Increased levels in vivo of mRNAs for IL-8 and macrophage inflammatory protein-1 alpha (MIP-1 alpha), but not of RANTES mRNA in peripheral blood mononuclear cells of patients with atopic dermatitis. Clin Exp Immunol. 1999;117:237–43. doi: 10.1046/j.1365-2249.1999.00982.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 176.Lippert U, Hoer A, Moller A, Ramboer I, Cremer B, Henz BM. Role of antigeninduced cytokine release in atopic pruritus. Int Arch Allergy Immunol. 1998;116:36–9. doi: 10.1159/000023922. [DOI] [PubMed] [Google Scholar]
  • 177.Buddenkotte J, Steinhoff M. Pathophysiology and therapy of pruritus in allergic and atopic diseases. Allergy. 2010;65:805–21. doi: 10.1111/j.1398-9995.2010.01995.x. [DOI] [PubMed] [Google Scholar]
  • 178.Chan LS, Robinson N, Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol. 2001;117:977–83. doi: 10.1046/j.0022-202x.2001.01484.x. [DOI] [PubMed] [Google Scholar]
  • 179.Gibbs BF. Human basophils as effectors and immunomodulators of allergic inflammation and innate immunity. Clin Exp Med. 2005;5:43–9. doi: 10.1007/s10238-005-0064-5. [DOI] [PubMed] [Google Scholar]
  • 180.Pieri L, Bogani C, Guglielmelli P, et al. The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica. 2009;94:1537–45. doi: 10.3324/haematol.2009.007047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 181.Saini SS. Basophil responsiveness in chronic urticaria. Curr Allergy Asthma Rep. 2009;9:286–90. doi: 10.1007/s11882-009-0040-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 182.O’Reilly M, Alpert R, Jenkinson S, et al. Identification of a histamine H4 receptor on human eosinophils--role in eosinophil chemotaxis. J Recept Signal Transduct Res. 2002;22:431–48. doi: 10.1081/rrs-120014612. [DOI] [PubMed] [Google Scholar]
  • 183.Shakoory B, Fitzgerald SM, Lee SA, Chi DS, Krishnaswamy G. The role of human mast cell-derived cytokines in eosinophil biology. J Interferon Cytokine Res. 2004;24:271–81. doi: 10.1089/107999004323065057. [DOI] [PubMed] [Google Scholar]
  • 184.Saint-Leger D, Kligman AM, Stoudemayer TJ. The role of the resident microflora in the pathogenesis of dandruff. J Soc Cosmet Chem. 1989;40:109–17. [Google Scholar]
  • 185.Jang SJ, Lim SH, Ko JH, et al. The Investigation on the Distribution of Malassezia Yeasts on the Normal Korean Skin by 26S rDNA PCR-RFLP. Ann Dermatol. 2009;21:18–26. doi: 10.5021/ad.2009.21.1.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 186.Kesavan S, Walters CE, Holland KT, Ingham E. The effects of Malassezia on pro-inflammatory cytokine production by human peripheral blood mononuclear cells in vitro. Med Mycol. 1998;36:97–106. [PubMed] [Google Scholar]
  • 187.Thomas DS, Ingham E, Bojar RA, Holland KT. In vitro modulation of human keratinocyte pro- and anti-inflammatory cytokine production by the capsule of Malassezia species. FEMS Immunol Med Microbiol. 2008;54:203–14. doi: 10.1111/j.1574-695X.2008.00468.x. [DOI] [PubMed] [Google Scholar]
  • 188.Boelsma E, Tanojo H, Boddé HE, Ponec M. An in vivo-In vitro study of the use of a human skin equivalent for irritancy screening of fatty acids. Toxicol In Vitro. 1997;11:365–76. doi: 10.1016/s0887-2333(97)00021-0. [DOI] [PubMed] [Google Scholar]
  • 189.Boelsma E, Tanojo H, Boddé HE, Ponec M. Assessment of the potential irritancy of oleic acid on human skin: Evaluation in vitro and in vivo. Toxicol In Vitro. 1996;10:729–42. doi: 10.1016/s0887-2333(96)00053-7. [DOI] [PubMed] [Google Scholar]
  • 190.Ro BI, Dawson TL. The role of sebaceous gland activity and scalp microfloral metabolism in the etiology of seborrheic dermatitis and dandruff. J Investig Dermatol Symp Proc. 2005;10:194–7. doi: 10.1111/j.1087-0024.2005.10104.x. [DOI] [PubMed] [Google Scholar]
  • 191.Kerr K, Darcy T, Henry J, et al. Epidermal changes associated with symptomatic resolution of dandruff: biomarkers of scalp health. Int J Dermatol. 2011;50:102–13. doi: 10.1111/j.1365-4632.2010.04629.x. [DOI] [PubMed] [Google Scholar]
  • 192.Tanojo H, Bouwstra JA, Junginger HE, Boddé HE. In vitro human skin barrier modulation by fatty acids: skin permeation and thermal analysis studies. Pharm Res. 1997;14:42–9. doi: 10.1023/a:1012099216060. [DOI] [PubMed] [Google Scholar]
  • 193.Tanojo H, Boelsma E, Junginger HE, Ponec M, Boddé HE. In vivo human skin barrier modulation by topical application of fatty acids. Skin Pharmacol Appl Skin Physiol. 1998;11:87–97. doi: 10.1159/000029813. [DOI] [PubMed] [Google Scholar]
  • 194.Nakabayashi A, Sei Y, Guillot J. Identification of Malassezia species isolated from patients with seborrheic dermatitis, atopic dermatitis, pityriasis vesicolor and normal subjects. Med Mycol. 2000;38:337–41. doi: 10.1080/mmy.38.5.337.341. [DOI] [PubMed] [Google Scholar]
  • 195.Sugita T, Suto H, Unno T, et al. Moleculer analysis of Malassezia microflora on the skin of atopic dermatitis patients and healthy subjects. J Clin Microbiol. 2001;39:3486–90. doi: 10.1128/JCM.39.10.3486-3490.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 196.Lindgren L, Wahlgren CF, Johansson SG, Wiklund I, Nordvall SL. Occurrence and clinical features of sensitization to Pityrosporum orbiculare and other allergens in children with atopic dermatitis. Acta Derm Venereol. 1995;75:300–4. doi: 10.2340/0001555575300304. [DOI] [PubMed] [Google Scholar]
  • 197.Dubin G. Extracellular proteases of Staphylococcus spp. Biol Chem. 2002;383:1075–86. doi: 10.1515/BC.2002.116. [DOI] [PubMed] [Google Scholar]
  • 198.Kotani A, Kusu F. HPLC with electrochemical detection for determining the distribution of free fatty acids in skin surface lipids from the human face and scalp. Arch Dermatol Res. 2002;294:172–7. doi: 10.1007/s00403-002-0308-0. [DOI] [PubMed] [Google Scholar]
  • 199.Zouboulis CC. The sebaceous gland. Hautarzt. 2010;61:467–77. doi: 10.1007/s00105-009-1894-y. [DOI] [PubMed] [Google Scholar]
  • 200.De Luca C, Valacchi G. Surface lipids as multifunctional mediators of skin responses to environmental stimuli. Mediators Inflamm. 2010;2010:321494. doi: 10.1155/2010/321494. Epub 2010 Oct 20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 201.Picardo M, Passi S, De Luca C, Morrone A, Bartoli F, Ippolito F. Skin surface lipids in patients affected with atopic dermatitis. In: Czernielewski JM, editor. Immunological and Pharmacological Aspects of Atopic and Contact Eczema. Pharmacology and the Skin. Vol. 4. 1991. pp. 173–4. [Google Scholar]
  • 202.Passi S, Picardo M, Morrone A, De Luca C, Ippolito F. Skin surface lipids in HIV sero-positive and HIV sero-negative patients affected with seborrheic dermatitis. J Dermatol Sci. 1991;2:84–91. doi: 10.1016/0923-1811(91)90016-q. [DOI] [PubMed] [Google Scholar]
  • 203.Fujita F, Azuma T, Tajiri M, Okamoto H, Sano M, Tominaga M. Significance of hair-dye base-induced sensory irritation. Int J Cosmet Sci. 2010;32:217–24. doi: 10.1111/j.1468-2494.2009.00564.x. [DOI] [PubMed] [Google Scholar]
  • 204.Elias PM, Feingold KR. Lipids and the epidermal water barrier: metabolism, regulation, and pathophysiology. Semin Dermatol. 1992;11:176–82. [PubMed] [Google Scholar]
  • 205.Elias PM, Menon GK. Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv Lipid Res. 1991;24:1–26. doi: 10.1016/b978-0-12-024924-4.50005-5. [DOI] [PubMed] [Google Scholar]
  • 206.Green SC, Stewart ME, Downing DT. Variation in sebum fatty acid composition among adult humans. J Invest Dermatol. 1984;83:114–7. doi: 10.1111/1523-1747.ep12263287. [DOI] [PubMed] [Google Scholar]
  • 207.Greene RS, Downing DT, Pochi PE, Strauss JS. Anatomical variation in the amount and composition of human skin surface lipid. J Invest Dermatol. 1970;54:240–7. doi: 10.1111/1523-1747.ep12280318. [DOI] [PubMed] [Google Scholar]
  • 208.O’goshi K, Iguchi M, Tagami H. Functional analysis of the stratum corneum of scalp skin: studies in patients with alopecia areata and androgenetic alopecia. Arch Dermatol Res. 2000;292:605–11. doi: 10.1007/s004030000185. [DOI] [PubMed] [Google Scholar]
  • 209.Tey HL, Yosipovitch G. Targeted treatment of pruritus - a look into the future. Br J Dermatol. 2011 Jan 11; doi: 10.1111/j.1365-2133.2011.10217.x. doi: 10.1111/j.1365-2133.2011.10217.x. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES